Cargando…

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study

BACKGROUND: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seamon, Leigh G, Java, James J, Monk, Bradley J, Penson, Richard T, Brown, Jubilee, Mannel, Robert S, Oaknin, Anna, Leitao, Mario M, Eisenhauer, Eric L, Long, Harry J, Liao, Shu Y, Tewari, Krishnansu S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785748/ https://www.ncbi.nlm.nih.gov/pubmed/29182608 http://dx.doi.org/10.1038/bjc.2017.400

Ejemplares similares

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
por: Tewari, Krishnansu S., et al.
Publicado: (2023)

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology
por: Wolford, Juliet E., et al.
Publicado: (2017)

Gynaecological Oncology
por: Osborne, R.J.
Publicado: (1993)

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
por: Pitiyarachchi, Omali, et al.
Publicado: (2022)

Gynaecological Oncology
por: Tindall, V. R.
Publicado: (1976)

Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
por: Gore, M. E., et al.
Publicado: (1997)

Manual of Gynaecologic Oncology
por: Hunter, R.
Publicado: (1981)

Clinical Gynaecologic Oncology
por: Hunter, R.
Publicado: (1981)

NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery
por: Chetvertkov, Mikhail, et al.
Publicado: (2020)

Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials
por: Hallemeier, Christopher L., et al.
Publicado: (2023)

Investigation of standardized training of radiation oncology residents for gynaecological tumours in China
por: Sun, Shuai, et al.
Publicado: (2023)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

NRG Oncology Survey of Monte Carlo Dose Calculation Use in US Proton Therapy Centers
por: Lin, Liyong, et al.
Publicado: (2021)

Gynaecologic Oncology Controversies in Cancer Treatment
por: Hunter, R.
Publicado: (1982)

Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology
por: Gensheimer, Michael F., et al.
Publicado: (2020)

Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC—UK gynaecological oncology surgical outcomes and complications)
por: Iyer, R, et al.
Publicado: (2015)

Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey()
por: Cook, Elise D., et al.
Publicado: (2018)

Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
por: Yom, Sue S., et al.
Publicado: (2021)

Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study
por: Casablanca, Yovanni, et al.
Publicado: (2022)

The Increasing Relevance of Tumour Histology in Determining Oncological Outcomes in Colorectal Cancer
por: Nagtegaal, Iris D., et al.
Publicado: (2015)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Updates on drug discovery in ovarian cancer
por: Gibson, Steven J, et al.
Publicado: (2014)

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study
por: Goodfellow, Paul J., et al.
Publicado: (2015)

Fast-Track Surgery in Gynaecology and Gynaecologic Oncology: A Review of a Rolling Clinical Audit
por: Carter, Jonathan
Publicado: (2012)

Improving attendance to genetic counselling services for gynaecological oncology patients
por: Pokharel, Hanoon P., et al.
Publicado: (2018)

Impact of COVID-19 on Gynaecological oncology; a global perspective
por: O'Neill, Danielle, et al.
Publicado: (2021)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

International Variations in Surgical Morbidity and Mortality Post Gynaecological Oncology Surgery: A Global Gynaecological Oncology Surgical Outcomes Collaborative Led Study (GO SOAR1)
por: Gaba, Faiza, et al.
Publicado: (2023)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022)

Assessment of morbidity in gynaecologic oncology laparoscopy and identification of possible risk factors
por: Peña-Fernández, Maite, et al.
Publicado: (2015)

Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients
por: Nezi-Cahn, Sandra, et al.
Publicado: (2019)

Management of Gynaecological oncology diseases during COVID-19 global pandemic
por: de Andrade Vieira, Marcelo, et al.
Publicado: (2020)

Evaluation of the clinical pharmacist services at a gynaecological oncology preadmission clinic
por: Triscari, Natasha, et al.
Publicado: (2022)

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
por: Santin, Alessandro D., et al.
Publicado: (2020)

Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
por: Patil, Nirav, et al.
Publicado: (2021)

Impact of COVID-19 in gynaecological oncology care: a systematic rapid review
por: Nikolopoulos, Manolis, et al.
Publicado: (2021)

RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
por: Bovi, Joseph, et al.
Publicado: (2019)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5adgtpgkk8hj46ujc8mqgtuha9